Opdivo

In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Fri, 03/10/23 - 11:20 am
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Endpoints
Tue, 03/7/23 - 10:37 pm
Bristol Myers Squibb
Germany
Opdivo
Opdualag
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Tue, 02/21/23 - 11:05 am
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
Tue, 12/6/22 - 10:31 am
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Thu, 10/20/22 - 10:41 am
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Thu, 09/15/22 - 11:15 pm
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Mon, 07/11/22 - 05:48 pm
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance
Fierce Pharma
Mon, 06/6/22 - 09:59 am
ASCO 2022
Bristol Myers Squibb
lung cancer
Opdivo
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Bristol needs to get fresh
EP Vantage
Fri, 05/6/22 - 10:45 am
Bristol Myers Squibb
Opdivo
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Mon, 04/18/22 - 11:42 pm
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
What’s next for Bristol Myers' relatlimab?
EP Vantage
Wed, 03/23/22 - 10:36 am
Bristol Myers Squibb
relatilimab
Opdivo
Opdualag
melanoma
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
Fierce Biotech
Mon, 03/14/22 - 10:24 am
Bristol Myers Squibb
Opdivo
Nektar Therapeutics
bempegaldesleukin
clinical trials
FDA hands Bristol Myers a landmark approval in early-stage lung cancer after just five days
Endpoints
Mon, 03/7/22 - 10:00 am
FDA
Bristol Myers Squibb
Opdivo
early-stage lung cancer
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
Fierce Pharma
Thu, 03/3/22 - 10:33 am
FDA
drug approvals
FibroGen
AstraZeneca
daprodustat
Bristol Myers Squibb
Opdivo
Roche
tiragolumab
Merck
favezelima
bInnovent
Eli Lilly
Akeso Biopharma
Sino Biopharmaceutical
Novartis
Ukoniq
TG Therapeutics
GW Pharmaceuticals
Marinus Pharmaceuticals
Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
Fierce Pharma
Mon, 02/28/22 - 11:32 am
Bristol Myers Squibb
FDA
Opdivo
priority review
non-small cell lung cancer
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
Mon, 01/10/22 - 11:49 pm
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Immuno-oncology spotlight falls on cervical cancer
EP Vantage
Tue, 12/7/21 - 10:39 am
immuno-oncology
cervical cancer
Opdivo
Keytruda
Bristol Myers Squibb
Merck
Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck
Endpoints
Mon, 11/8/21 - 10:58 am
Bristol Myers Squibb
Merck
Opdivo
lung cancer
Keytruda

Pages